Last reviewed · How we verify
Iron bisglycinate Oral Tablet
Iron bisglycinate Oral Tablet is a Iron supplement Small molecule drug developed by Hatem AbuHashim. It is currently in Phase 3 development for Iron deficiency anemia, Iron supplementation in pregnancy or lactation.
Iron bisglycinate provides bioavailable iron in a chelated form that is absorbed in the gastrointestinal tract to replenish iron stores and support hemoglobin synthesis.
Iron bisglycinate provides bioavailable iron in a chelated form that is absorbed in the gastrointestinal tract to replenish iron stores and support hemoglobin synthesis. Used for Iron deficiency anemia, Iron supplementation in pregnancy or lactation.
At a glance
| Generic name | Iron bisglycinate Oral Tablet |
|---|---|
| Sponsor | Hatem AbuHashim |
| Drug class | Iron supplement |
| Target | Iron (Fe2+) for hemoglobin and myoglobin synthesis |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Iron bisglycinate is a chelate complex of iron bound to the amino acid glycine, which enhances intestinal absorption compared to non-chelated iron salts. The glycine ligand protects iron from interactions with dietary inhibitors and reduces gastrointestinal irritation. Once absorbed, iron is incorporated into hemoglobin and myoglobin, and stored as ferritin to treat or prevent iron deficiency anemia.
Approved indications
- Iron deficiency anemia
- Iron supplementation in pregnancy or lactation
Common side effects
- Gastrointestinal upset (nausea, constipation, abdominal discomfort)
- Dark stools
- Headache
Key clinical trials
- Potential Harms of Untargeted Iron Supplementation in Cambodia Where Iron Deficiency is Not the Cause of Anemia (PHASE4)
- Iron Sucrose Versus Ferrous Bis-glycinate for Treatment of Iron Deficiency Anemia (PHASE3)
- Efficacy of Iron Bisglycinate in Treatment of Iron Deficiency Anemia in Pregnant Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron bisglycinate Oral Tablet CI brief — competitive landscape report
- Iron bisglycinate Oral Tablet updates RSS · CI watch RSS
- Hatem AbuHashim portfolio CI
Frequently asked questions about Iron bisglycinate Oral Tablet
What is Iron bisglycinate Oral Tablet?
How does Iron bisglycinate Oral Tablet work?
What is Iron bisglycinate Oral Tablet used for?
Who makes Iron bisglycinate Oral Tablet?
What drug class is Iron bisglycinate Oral Tablet in?
What development phase is Iron bisglycinate Oral Tablet in?
What are the side effects of Iron bisglycinate Oral Tablet?
What does Iron bisglycinate Oral Tablet target?
Related
- Drug class: All Iron supplement drugs
- Target: All drugs targeting Iron (Fe2+) for hemoglobin and myoglobin synthesis
- Manufacturer: Hatem AbuHashim — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Iron deficiency anemia
- Indication: Drugs for Iron supplementation in pregnancy or lactation
- Compare: Iron bisglycinate Oral Tablet vs similar drugs
- Pricing: Iron bisglycinate Oral Tablet cost, discount & access